 Key data includes results for intravenous administration of Rylaze asparaginase erwinia chrysanthemi recombinant-rywn in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Patients DUBLIN , Nov. 3, 2022 PRNewswire -- Jazz Pharmaceuticals plc Nasdaq: JAZZ today announced that 13 abstracts will be presented at the American Society of Hematology ASH Annual Meeting from December 10-13, 2022. Research findings to be presented include data from company-sponsored, investigator-sponsored and collaborative trials for Rylaze asparaginase erwinia chrysanthemi recombinant-rywnasparaginase, Vyxeos daunorubicin and cytarabine, also known as JZP351, and Defitelio defibrotide sodium. 